K
Kotaro Kodama
Researcher at Eisai
Publications - 12
Citations - 812
Kotaro Kodama is an academic researcher from Eisai. The author has contributed to research in topics: Lenvatinib & Cancer. The author has an hindex of 6, co-authored 11 publications receiving 566 citations.
Papers
More filters
Journal ArticleDOI
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama,Junji Matsui,Kotaro Kodama,Naoko Hata-Sugi,Takayuki Kimura,Kiyoshi Okamoto,Yukinori Minoshima,Masao Iwata,Yasuhiro Funahashi +8 more
TL;DR: Data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Journal ArticleDOI
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Kiyoshi Okamoto,Kotaro Kodama,Kazuma Takase,Naoko Hata Sugi,Yuji Yamamoto,Masao Iwata,Akihiko Tsuruoka +6 more
TL;DR: It is demonstrated that lenvatinib can exert antitumor activity againstRET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.
Journal ArticleDOI
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
Takayuki Kimura,Yu Kato,Yoichi Ozawa,Kotaro Kodama,Junichi Ito,Kenji Ichikawa,Kazuhiko Yamada,Yusaku Hori,Kimiyo Tabata,Kazuma Takase,Junji Matsui,Yasuhiro Funahashi,Kenichi Nomoto +12 more
TL;DR: Lenvatinib has immunomodulatory activity that contributes to the antitumor activity of lenvatinIB and enhances the antitUMor activity in combination treatment with anti‐PD‐1 antibody, and warrants further investigation against advanced HCC.
Journal ArticleDOI
Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
Yusuke Narita,Kiyoshi Okamoto,Megumi Kawada,Kazuma Takase,Yukinori Minoshima,Kotaro Kodama,Masao Iwata,Norimasa Miyamoto,Kohei Sawada +8 more
TL;DR: E6201 is more effective against BRAF-V600E mutant melanoma compared with BRAF wild-type melanoma based on MEK inhibition and the effectiveness of E6201 in this preclinical study is a result of its binding with MEK1 far from the C121S point mutation so the mutation is unable to influence the MAPK pathway inhibitory activity.
Journal ArticleDOI
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Saori Watanabe Miyano,Saori Watanabe Miyano,Yuji Yamamoto,Kotaro Kodama,Yukiko Miyajima,Masaki Mikamoto,Takayuki Nakagawa,Hiroko Kuramochi,Setsuo Funasaka,Nagao Satoshi,Naoko Hata Sugi,Kiyoshi Okamoto,Yukinori Minoshima,Yusuke Nakatani,Yuki Karoji,Isao Ohashi,Yoshinobu Yamane,Toshimi Okada,Tomohiro Matsushima,Junji Matsui,Masao Iwata,Toshimitsu Uenaka,Akihiko Tsuruoka +22 more
TL;DR: E7090 showed selective antiproliferative activity against cancer cell lines harboring FGFR genetic abnormalities and decreased tumor size in a mouse xenograft model using cell lines with dysregulated FGFR.